Search Results - Marion Subklewe
- Showing 1 - 3 results of 3
-
1
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups by Ricarda Knabe, Philippe Muller, Christoph Schliemann, Maher Hanoun, Julia Marie Unglaub, Barbora Weinbergerová, Jiří Mayer, Carolin Krekeler, Stefan W. Krause, Martin Kaufmann, Sabrina Kraus, Björn Steffen, Franziska Modemann, Marion Subklewe, Veit Bücklein, Wolfgang G. Kunz, Martina Rudelius, Michael von Bergwelt-Baildon, Katja Gutmair, Eva Hoster, Tobias Herold, Christoph Röllig, Karsten Spiekermann
Published 2025-07-01
Article -
2
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia by Martin Hutchings, Koorosh Korfi, Pau Montesinos, Armando Santoro, Hsin-An Hou, Pilar Martinez-Sanchez, Susana Vives, Sara Galimberti, Tsai-Yun Chen, Marco Frigeni, Sylvain Garciaz, Olga Salamero Garcia, Su-Peng Yeh, Karen Yee, Jordi Esteve, Ashish Bajel, Shaun Fleming, Anne Catherine Bretz, Jan Attig, Min Sun, Sina Nassiri, Tobias Rutishauser, Christian Klein, Y. May Ma, Gabriel Schnetzler, Stephanie Vauleon, Huixin Yu, Teresa Barata, Muriel Richard, Silke Simon, Heather Hinton, Nino Keshelava, Marion Subklewe
Published 2025-08-01
Article -
3
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study by Evgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, Meng Wang, Thomas Melchardt, Udo Holtick, Ulrike Bacher, Philipp Staber, Paolo Mazzeo, Corinna Leng, David Böckle, Alexander Hölscher, Joseph Kauer, Natalia Rotter, Vladan Vucinic, Jakob Rudzki, David Nachbaur, Veit Bücklein, Ulf Schnetzke, Isabelle Krämer, Kai Wille, Alexander Hasse, Bastian von Tresckow, Mathias Hänel, Christian Koenecke, Giuliano Filippini Velazquez, Andreas Viardot, Christoph Schmid, Lorenz Thurner, Dominik Wolf, Marion Subklewe, Martin Dreyling, Peter Dreger, Sascha Dietrich, Ulrich Keller, Ulrich Jäger, Richard Greil, Thomas Pabst, Georg Lenz, Björn Chapuy
Published 2025-08-01
Article